Accessed June 23, 2023. Drugs approved for lung cancer (no date) National Cancer Institute. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/lung (Accessed June 23, 2023. Lung cancer medications: Treatment types & combinations (2023) Lung Cancer Center. Available at: https:/...
The present invention relates to methods for predicting a probability of responsiveness to treatment with a folate alpha receptor targeting agent (fra) in a patient having a fra-expressing lung cancer. Methods for treating fra expressing lung cancer in a patient with a fra targeting agent are ...
Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer Ji Eun Shin Hyun Ae Jung Byoung Yong Shim ResearchOpen Access07 Feb 2025Scientific Reports Volume: 15, P: 4593 Massively parallel variant-to-function mapping determines functional regula...
Second-line treatment options for patients with relapsed, extensive-stage small cell lung cancer (ES-SCLC) are limited, and even with currently available t
Shopping for lung cancer treatment: Nineteen states and the District of Columbia have enacted oral chemotherapy access laws[15] that require private health plans to cover cancer drugs as they would cover traditional intravenous infusion therapy. ...
Demand for Combination Therapies for Lung Cancer Treatment is on the Rise New combination therapies in immuno-oncology are expanding treatment options for lung cancer. These therapies are especially beneficial for patients with advanced or metastatic disease. By combining immune checkpoint inhibitors with ...
<PreviousLung Cancer Next>Lung Cancer Diagnosis The treatment plan for lung cancer depends on the size, location, extent of the disease, and the patient’s physical condition. In St.Stamford Modern Cancer Hospital Guangzhou, experts from Multidisciplinary Team will jointly hold a consultation and di...
Lung cancer is the leading cause of cancer-associated mortality worldwide1. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx s
State of the Art: Concise ReviewTreatment Paradigms for Advanced Stage Non-small Cell Lung Cancer in the Era of Multiple Lines of Therapy Author links open overlay panelThomas E. Stinchcombe MD, Mark A. Socinski MDShow more Add to Mendeley Share Cite...
FDA grants priority review to oral non-small cell lung cancer drug The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with locally advanced or metastatic non-small cell lung cancer, accor...